Medicinsk Lustgas Strandmollen: Uses, Dosage & Side Effects
Medical-grade nitrous oxide (N₂O) used for procedural analgesia, labor pain relief, and sedation in clinical settings
Medicinsk Lustgas Strandmollen is a medical-grade nitrous oxide (N₂O, also known as “laughing gas”) used for analgesia and conscious sedation in clinical settings. Nitrous oxide has been used in medicine for over 170 years and remains one of the safest and most widely used analgesic gases worldwide. It is commonly administered as a premixed 50:50 blend with oxygen for labor pain, emergency analgesia, procedural sedation in adults and children, and as an adjunct to general anaesthesia. Its rapid onset (2–5 minutes) and equally rapid offset make it an ideal agent for short-duration pain relief where a quick recovery is essential. Nitrous oxide is listed on the WHO Model List of Essential Medicines and is recommended by NICE and ESA guidelines.
Quick Facts: Medicinsk Lustgas Strandmollen
Key Takeaways
- Nitrous oxide provides rapid, effective analgesia: With onset in 2–5 minutes and offset within 3–5 minutes of stopping, it is ideal for short painful procedures, labor pain, and emergency analgesia without prolonged sedation.
- Safe for conscious sedation: At standard analgesic concentrations (50–70% N₂O with oxygen), patients remain conscious, maintain protective airway reflexes, and can communicate with medical staff throughout the procedure.
- Contraindicated in air-filled cavities: Do not use if you have a pneumothorax, bowel obstruction, middle ear pathology, or decompression sickness, as nitrous oxide expands gas-filled spaces and can worsen these conditions.
- Prolonged or repeated use carries neurological risk: Nitrous oxide irreversibly inactivates vitamin B12, which can lead to megaloblastic anemia and subacute combined degeneration of the spinal cord with prolonged or frequent exposure.
- Widely used in labor and pediatrics: Nitrous oxide is one of the most established methods of labor analgesia worldwide and is also well-proven for pediatric procedural sedation in children old enough to self-administer (typically age 4+).
What Is Medicinsk Lustgas Strandmollen and What Is It Used For?
Medicinsk Lustgas Strandmollen is pharmaceutical-grade nitrous oxide (N₂O), a colorless gas with a faintly sweet odor that provides analgesic, anxiolytic, and mild sedative effects when inhaled. It is used for pain relief during labor, procedural sedation, emergency analgesia, and as a supplement to general anaesthesia.
Nitrous oxide was first synthesized by Joseph Priestley in 1772, and its analgesic properties were demonstrated by Humphry Davy in 1799. Since Horace Wells introduced it for dental anaesthesia in 1844, it has become one of the most enduring and widely used agents in clinical practice. Today, medical nitrous oxide is manufactured under strict pharmaceutical standards and is recognized by the WHO, EMA, and FDA as a safe and effective analgesic and anaesthetic agent.
The gas works through multiple pharmacological mechanisms. Its primary analgesic action occurs via antagonism of N-methyl-D-aspartate (NMDA) receptors in the central nervous system, which are key mediators of pain signaling. Additionally, nitrous oxide activates the endogenous opioid system by stimulating the release of enkephalins and endorphins, contributing to pain relief that is comparable to low-dose opioid analgesia. The anxiolytic and mild euphoric effects are mediated through modulation of GABA-A receptors and noradrenergic pathways, which explains why the gas historically earned the nickname “laughing gas.”
A key pharmacokinetic advantage of nitrous oxide is its low blood-gas partition coefficient (0.47), meaning it moves very rapidly between the lungs and the bloodstream. This results in fast onset of action (typically within 2–5 minutes of inhalation) and equally fast recovery (within 3–5 minutes of stopping). Unlike most sedative drugs, nitrous oxide does not accumulate in the body with repeated use during a single session, and it is eliminated almost entirely through the lungs in unchanged form.
Approved Clinical Uses
Nitrous oxide is approved and widely used for the following clinical indications, with strong evidence supporting its efficacy and safety in each setting:
- Labor analgesia: As a 50:50 mixture with oxygen (Entonox/Livopan), nitrous oxide is one of the most widely used methods of labor pain relief globally. It is inhaled through a demand valve mouthpiece or face mask during contractions, providing effective pain relief while allowing the mother to remain fully conscious and mobile.
- Procedural sedation and analgesia: Used for painful medical procedures such as wound suturing, abscess drainage, fracture reduction, joint injection, burn dressing changes, bone marrow biopsy, and lumbar puncture. Particularly valuable because recovery is rapid enough for same-day discharge.
- Pediatric procedural pain: Well-established for use in children for emergency department procedures, dental treatments, and minor surgery. The child must be cooperative enough to self-administer, typically from age 4–5 years.
- Emergency and pre-hospital analgesia: Widely used by paramedics and emergency medical teams for trauma, burns, fractures, and acute pain management in the field. The 50:50 premixed cylinders are portable and do not require complex equipment.
- Adjunct to general anaesthesia: Pure nitrous oxide (100%) can be mixed with other anaesthetic agents during general anaesthesia to reduce the required dose of volatile anaesthetics (MAC reduction) and opioids, potentially improving hemodynamic stability and reducing side effects.
- Dental anaesthesia and sedation: Used in dental practices worldwide for anxiolysis and pain relief during procedures, typically delivered through a nasal mask at concentrations of 30–50% with oxygen.
For procedural sedation, nitrous oxide is typically self-administered by the patient through a demand valve system. The patient holds the mouthpiece or mask and inhales when needed. If the patient becomes overly sedated, they will naturally stop inhaling (the mask falls away), providing an inherent safety mechanism. This “fail-safe” feature makes nitrous oxide one of the safest sedation methods available when used at analgesic concentrations.
What Should You Know Before Using Medicinsk Lustgas Strandmollen?
Before using nitrous oxide, your healthcare provider must assess you for contraindications, particularly conditions involving trapped gas in body cavities. Nitrous oxide is 34 times more soluble than nitrogen in blood, which means it rapidly diffuses into air-filled spaces and can cause dangerous expansion.
While nitrous oxide has an excellent safety profile when used appropriately, certain medical conditions and circumstances make its use hazardous or contraindicated. The most critical consideration is the gas’s physical property of diffusing into gas-filled spaces faster than nitrogen can diffuse out, leading to expansion of these spaces. In a closed body cavity, this expansion can cause serious, potentially life-threatening complications.
Healthcare providers must conduct a thorough medical history before administering nitrous oxide. The assessment should include questions about respiratory conditions, recent surgeries (especially involving the ear, eye, or abdomen), diving history, vitamin B12 status, and current medications. Patients should also be informed about the expected effects and the self-administration technique.
Contraindications – Do Not Use Nitrous Oxide If You:
- Have or are suspected to have a pneumothorax (collapsed lung) or any condition where air is trapped in the pleural space, as nitrous oxide will expand the trapped gas and worsen respiratory compromise
- Have a bowel obstruction or any condition with trapped gas in the gastrointestinal tract, including paralytic ileus
- Have recently had middle ear surgery or have middle ear disease with air entrapment, as gas expansion can damage the tympanic membrane or disrupt surgical repair
- Have maxillofacial injuries where air may be trapped in tissue planes, particularly around the orbit
- Have decompression sickness or have recently been diving with compressed air (typically within 24 hours), as nitrogen bubbles in the blood can expand dangerously
- Are severely intoxicated with alcohol or drugs or have significantly altered consciousness where cooperation with self-administration is not possible
- Have a known or suspected severe vitamin B12 deficiency or diagnosed pernicious anemia, as nitrous oxide will further inactivate B12
- Have a condition that requires high-concentration oxygen therapy (such as severe respiratory failure), as nitrous oxide dilutes the inspired oxygen concentration
Nitrous oxide is 34 times more soluble than nitrogen in blood. In any closed gas-filled body cavity, nitrous oxide diffuses in faster than nitrogen diffuses out, causing the space to expand. In a pneumothorax, this can convert a stable condition into a tension pneumothorax within minutes, which is a life-threatening emergency. Always rule out pneumothorax before administering nitrous oxide to trauma patients.
Warnings and Precautions
Discuss the following conditions with your healthcare provider, as they may require additional monitoring or caution during nitrous oxide use:
- Vitamin B12 deficiency risk factors: Patients who are vegan, have malabsorption disorders (such as celiac disease or Crohn’s disease), elderly patients with poor nutrition, or those on long-term proton pump inhibitors (PPIs) may have subclinical B12 deficiency that nitrous oxide could unmask or worsen
- Chronic obstructive pulmonary disease (COPD): While not an absolute contraindication, patients with severe COPD may have impaired gas exchange that affects the uptake and elimination of nitrous oxide
- Raised intracranial pressure: Nitrous oxide may slightly increase intracranial pressure; caution is advised in patients with head injuries or intracranial hypertension
- First trimester of pregnancy: Although nitrous oxide is considered safe for labor analgesia, its use during early pregnancy (first trimester) should be avoided due to theoretical teratogenic concerns observed in animal studies at prolonged high exposures
- Impaired consciousness or inability to cooperate: The self-administration safety mechanism relies on the patient being able to hold and use the delivery device. If the patient cannot cooperate, clinician-administered nitrous oxide requires additional monitoring
Pregnancy and Breastfeeding
Nitrous oxide has different risk profiles depending on the stage of pregnancy and duration of exposure. Understanding these distinctions is important for both patients and healthcare providers.
Labor and delivery: Nitrous oxide (50:50 with oxygen) is one of the most widely used and well-studied analgesic agents for labor. Decades of clinical experience and multiple systematic reviews confirm its safety during active labor. The gas crosses the placenta but is rapidly eliminated by both mother and newborn through respiration. Apgar scores and neonatal outcomes are not adversely affected by intrapartum nitrous oxide use. It is endorsed by NICE, the American College of Nurse-Midwives (ACNM), and numerous international obstetric guidelines.
Early pregnancy (first trimester): Nitrous oxide should be avoided during the first trimester. Animal studies have shown that prolonged exposure at high concentrations during organogenesis can cause teratogenic effects, likely related to interference with methionine synthase and DNA metabolism via B12 inactivation. While short clinical exposures have not been definitively linked to human birth defects, the precautionary principle applies.
Breastfeeding: Nitrous oxide is rapidly eliminated through the lungs after discontinuation. Due to its extremely short half-life and negligible accumulation in body tissues, it is considered compatible with breastfeeding. No specific waiting period is required before breastfeeding after nitrous oxide exposure.
Pregnant healthcare workers should minimize chronic occupational exposure to waste nitrous oxide. Effective scavenging systems should be in place in all clinical areas where nitrous oxide is used. National exposure limits (typically 100 ppm for 8-hour TWA) should be strictly observed.
How Does Medicinsk Lustgas Strandmollen Interact with Other Drugs?
Nitrous oxide has a relatively narrow interaction profile compared to many systemic medications, but important interactions exist with other CNS depressants, certain chemotherapy agents, and drugs that affect vitamin B12 metabolism. The most clinically significant interactions involve additive sedation with opioids and benzodiazepines.
Because nitrous oxide is administered by inhalation and rapidly eliminated through the lungs without hepatic metabolism, it has fewer pharmacokinetic drug interactions than most medications. However, its pharmacodynamic interactions – particularly the additive effects on the central nervous system with other sedative agents – are clinically important and must be considered before administration.
Major Interactions (Clinically Significant)
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Opioid analgesics (morphine, fentanyl, codeine) | Additive CNS depression and respiratory depression; nitrous oxide potentiates opioid analgesia via endogenous opioid pathway activation | Reduce opioid dose when combining; monitor respiratory rate and oxygen saturation closely |
| Benzodiazepines (midazolam, diazepam) | Enhanced sedation, increased risk of over-sedation and loss of protective reflexes | Use lower sedation doses; continuous monitoring of consciousness level required |
| Other general anaesthetics (sevoflurane, propofol) | Nitrous oxide reduces the minimum alveolar concentration (MAC) of volatile anaesthetics by up to 60%; additive CNS depression with intravenous anaesthetics | Intended therapeutic interaction in anaesthesia; reduce doses of co-administered agents accordingly |
| Methotrexate | Both methotrexate and nitrous oxide impair folate metabolism; combined exposure can cause severe bone marrow suppression | Avoid nitrous oxide in patients on methotrexate therapy; risk of aplastic crisis |
| Bleomycin | Nitrous oxide at high concentrations may potentiate bleomycin-induced pulmonary toxicity due to oxygen-related lung injury mechanisms | Avoid or use with extreme caution in patients who have received bleomycin |
Other Important Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Vitamin B12 supplements | Nitrous oxide irreversibly oxidizes the cobalt ion in vitamin B12 (cobalamin), rendering it inactive as a cofactor for methionine synthase | B12 supplementation before or after may mitigate risk in repeated exposures; does not prevent acute inactivation |
| Alcohol | Additive CNS depression; increased nausea and vomiting risk | Avoid nitrous oxide in acutely intoxicated patients |
| Phenothiazines and other antiemetics | May mask early signs of nitrous oxide-induced nausea, a useful clinical indicator of adequate analgesia | Not a contraindication; monitor sedation level |
What Is the Correct Dosage of Medicinsk Lustgas Strandmollen?
Nitrous oxide is administered by inhalation, typically as a premixed 50:50 combination with oxygen for procedural analgesia, or at concentrations of 50–70% with oxygen during general anaesthesia. The exact concentration and duration are determined by the clinical indication and the patient’s response.
Unlike most medications, nitrous oxide dosing is not measured in milligrams but rather as a percentage concentration of the inspired gas mixture. The key principle of safe nitrous oxide administration is that the minimum inspired oxygen concentration must never fall below 21% (ambient air level), and in practice, most clinical applications use at least 30% oxygen. Modern anaesthesia machines have hypoxic guard systems that prevent delivery of less than 25–30% oxygen.
Adults
Procedural Analgesia and Sedation
Concentration: 50% N₂O + 50% O₂ (premixed as Entonox/Livopan) via demand valve mouthpiece or face mask
Administration: Self-administered by the patient. Begin inhalation 2–3 minutes before the procedure. Continue as needed during the procedure. Maximum recommended continuous duration is typically 6 hours in a single session, though most procedures are much shorter.
Onset: 2–5 minutes to peak effect
Recovery: 3–5 minutes after stopping inhalation
Labor Analgesia
Concentration: 50% N₂O + 50% O₂
Administration: Self-administered via mouthpiece. Begin inhaling at the start of a contraction (or 30 seconds before if contractions are predictable). Stop inhaling between contractions. Continue as needed throughout labor.
Duration: May be used throughout active labor. There is no strict maximum duration for labor use.
General Anaesthesia (Adjunct)
Concentration: 50–70% N₂O with 30–50% O₂ (never below 30% O₂)
Administration: Administered by the anaesthetist via the anaesthesia machine. Used in combination with volatile anaesthetics (sevoflurane, desflurane) or intravenous agents (propofol). Reduces the required MAC of co-administered anaesthetics.
Discontinuation: At the end of anaesthesia, administer 100% O₂ for at least 5 minutes to prevent diffusion hypoxia.
Children
Pediatric Procedural Sedation
Age requirement: Child must be old enough to understand instructions and self-administer (typically 4–5 years and older)
Concentration: 50% N₂O + 50% O₂ via age-appropriate face mask or mouthpiece
Administration: Same self-administration principle as adults. Allow 3–5 minutes for full effect before beginning the procedure. Trained staff must monitor throughout.
Duration: Keep as short as clinically necessary; typically 15–30 minutes for most pediatric procedures
Dental Sedation in Children
Concentration: 30–50% N₂O with 50–70% O₂ delivered via nasal mask
Administration: Titrated by the dental professional. Start at 30% and increase gradually until desired sedation level is achieved. Child must be breathing through the nose.
Elderly
Elderly Patients
Concentration: Same as adults (50% N₂O + 50% O₂)
Special considerations: Elderly patients may be more sensitive to the sedative effects. They may have reduced pulmonary function affecting gas uptake. Screen for vitamin B12 deficiency before repeated administration. Use with increased monitoring for sedation depth and respiratory function.
After Discontinuation
When nitrous oxide is discontinued, it rapidly exits the bloodstream into the alveoli, temporarily diluting the oxygen in the lungs. This phenomenon, called diffusion hypoxia (or the Fink effect), can cause transient oxygen desaturation. To prevent this, patients should breathe supplemental 100% oxygen or, at minimum, well-oxygenated room air for 3–5 minutes after stopping nitrous oxide. This is particularly important after prolonged or high-concentration use and in patients with respiratory compromise.
Overdose
Overdose with nitrous oxide in a clinical setting is uncommon because of the self-administration safety mechanism and the fact that the gas is always co-administered with oxygen. However, if excessive concentrations are delivered (approaching or exceeding 70% N₂O), or if a patient loses consciousness and continues to receive nitrous oxide, hypoxia can result from insufficient inspired oxygen.
Signs of excessive nitrous oxide effect include: deep sedation or unresponsiveness, loss of the ability to hold the mouthpiece, cyanosis (blue discoloration of lips or fingertips), and decreased oxygen saturation on pulse oximetry. Management involves immediately discontinuing nitrous oxide, administering 100% oxygen, ensuring airway patency, and providing supportive care. There is no specific antidote for nitrous oxide.
What Are the Side Effects of Medicinsk Lustgas Strandmollen?
The most common side effects of nitrous oxide are nausea, vomiting, dizziness, and light-headedness, which occur in approximately 10–15% of patients. These effects are transient and typically resolve within minutes of stopping inhalation. Serious adverse effects are rare with appropriate clinical use.
Nitrous oxide has an excellent safety profile when administered in controlled clinical settings with appropriate oxygen supplementation and monitoring. Most side effects are related to the central nervous system and gastrointestinal tract and are dose-dependent. The unique advantage of nitrous oxide is that virtually all acute side effects resolve rapidly upon discontinuation, usually within 3–5 minutes, because the gas is eliminated unchanged through the lungs.
The incidence and severity of side effects depend on the concentration used, the duration of exposure, the patient’s underlying health, and whether other CNS depressants are co-administered. At the standard 50:50 mixture used for procedural analgesia, side effects are generally mild and well-tolerated. Higher concentrations used during general anaesthesia carry a higher incidence of nausea and vomiting.
Very Common
Affects more than 1 in 10 people
- Dizziness and light-headedness
- Euphoria or sense of detachment
- Tingling or numbness in extremities (paresthesia)
Common
Affects 1 in 10 to 1 in 100 people
- Nausea
- Vomiting
- Drowsiness
- Headache
- Excessive sweating
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Feeling of pressure in the middle ear
- Abdominal distension
- Excessive sedation
- Agitation or dysphoria (especially in children)
- Vivid dreams or hallucinations
Rare
Affects fewer than 1 in 1,000 people
- Diffusion hypoxia (if oxygen not given after stopping)
- Megaloblastic anemia (with prolonged or repeated use)
- Peripheral neuropathy (with chronic exposure)
- Subacute combined degeneration of the spinal cord (chronic/repeated use)
- Bone marrow suppression (prolonged exposure >24 hours)
Nitrous oxide irreversibly oxidizes the cobalt ion in vitamin B12 (cobalamin), converting it from its active Co(I) state to inactive Co(III). This inactivates the enzyme methionine synthase, which is essential for DNA synthesis, myelin formation, and folate metabolism. A single short clinical exposure typically has no measurable clinical effect in patients with normal B12 stores. However, prolonged continuous use (longer than 6–12 hours), repeated frequent exposures, or use in patients with pre-existing B12 deficiency can cause megaloblastic bone marrow changes within 24 hours and neurological damage (subacute combined degeneration) within days to weeks. This is the most important long-term safety concern with nitrous oxide.
How Should You Store Medicinsk Lustgas Strandmollen?
Medical nitrous oxide is supplied in compressed gas cylinders that must be stored upright in well-ventilated areas, away from heat sources, at temperatures between −20°C and +50°C. Cylinders must be secured to prevent falling and kept away from flammable materials.
Proper storage and handling of medical gas cylinders is critical for safety. Nitrous oxide is stored under high pressure (typically 44 bar at 15°C) and the gas supports combustion, meaning that while it does not burn itself, it will vigorously support the burning of other materials in an enriched atmosphere. Incorrect storage can lead to fire hazards, explosive release of gas, or degradation of the cylinder and its contents.
Storage Requirements
- Temperature: Store between −20°C and +50°C. Avoid exposure to extreme heat or direct sunlight, as this increases cylinder pressure and can compromise safety valves. In cold conditions (below −7°C), the premixed Entonox formulation may separate into its component gases, requiring careful re-mixing before use.
- Ventilation: Store in well-ventilated areas. Nitrous oxide is heavier than air (relative density 1.53) and can accumulate at floor level in poorly ventilated spaces, creating an asphyxiation hazard.
- Position: Store cylinders upright (vertical) and secured with chains, straps, or in purpose-built racks to prevent them from falling.
- Separation: Keep nitrous oxide cylinders at least 3 meters away from flammable gases (acetylene, hydrogen) and combustible materials (oils, greases, organic solvents).
- Labeling: Medical nitrous oxide cylinders are identified by international color coding – blue body in most countries following ISO standards. Never use a cylinder that is unlabeled, damaged, or past its test date.
- Access: Cylinders should be stored in locked, designated areas accessible only to authorized personnel.
Premixed nitrous oxide and oxygen cylinders (Entonox/Livopan) require special attention. These should be stored horizontally for at least 24 hours before use if they have been stored below 0°C, and inverted three times before administration to ensure complete mixing. If the cylinders are stored in conditions where the temperature may have dropped below −7°C, the Poynting effect can cause the gases to separate, with oxygen-rich gas delivered first followed by a dangerously hypoxic nitrous oxide–rich mixture.
Environmental Considerations
Nitrous oxide is a potent greenhouse gas with a global warming potential approximately 273 times that of carbon dioxide over a 100-year period. Healthcare facilities should implement waste gas scavenging systems and minimize unnecessary venting. Used cylinders should be returned to the supplier for refilling or proper disposal according to local environmental regulations.
What Does Medicinsk Lustgas Strandmollen Contain?
Medicinsk Lustgas Strandmollen contains 100% nitrous oxide (dinitrogen monoxide, N₂O) as the sole active ingredient. It is a pure pharmaceutical-grade gas with no excipients, solvents, or additives.
Nitrous oxide (N₂O) is a simple inorganic compound consisting of two nitrogen atoms and one oxygen atom. At room temperature and atmospheric pressure, it is a colorless gas with a faintly sweet taste and odor. It is non-flammable itself but supports combustion, meaning it can make other materials burn more vigorously, similar to pure oxygen.
Active Ingredient
- Nitrous oxide (dinitrogen monoxide, N₂O): 100% v/v, pharmaceutical grade compliant with the European Pharmacopoeia (Ph. Eur.) monograph for medicinal nitrous oxide. Minimum purity 98.0% N₂O, with specified limits for impurities including carbon monoxide (CO <5 ppm), carbon dioxide (CO₂ <300 ppm), nitrogen dioxide (NO₂ <2 ppm), and moisture content.
Physical Properties
| Property | Value |
|---|---|
| Chemical formula | N₂O (dinitrogen monoxide) |
| Molecular weight | 44.01 g/mol |
| Boiling point | −88.5°C at atmospheric pressure |
| Vapor pressure | 51.7 bar at 20°C |
| Relative density (gas) | 1.53 (heavier than air) |
| Blood-gas partition coefficient | 0.47 (very low – rapid onset/offset) |
| Color and odor | Colorless; faintly sweet taste and odor |
| Flammability | Non-flammable; supports combustion |
Cylinder Information
Medicinsk Lustgas Strandmollen is supplied in high-pressure compressed gas cylinders made of steel or aluminum alloy. The cylinder pressure at 15°C is approximately 44 bar. Cylinders are available in various sizes depending on clinical requirements, from small portable cylinders for emergency use to large cylinders for hospital installations. All cylinders are fitted with a pin-index safety system (PISS) or diameter-index safety system (DISS) to prevent connection to incorrect gas supply systems.
The gas does not contain any preservatives, excipients, solvents, or propellants. The product is entirely composed of the active ingredient, manufactured by separation from air using fractional distillation and further purified to pharmaceutical standards.
Frequently Asked Questions About Medicinsk Lustgas Strandmollen
Medical nitrous oxide is used as an analgesic and anxiolytic gas in various clinical settings. Its most common uses include labor pain relief (where the mother self-administers via a mouthpiece during contractions), procedural sedation for minor surgical and dental procedures, emergency pain management for trauma and fractures, and as a component of general anaesthesia where it reduces the required dose of other anaesthetic agents. It is particularly valued for its rapid onset (2–5 minutes) and equally rapid recovery (3–5 minutes after stopping), making it ideal for situations where prolonged sedation is undesirable.
Nitrous oxide is widely used and considered safe for labor analgesia when administered as a 50:50 mixture with oxygen. Multiple systematic reviews and decades of clinical experience confirm that intrapartum use does not adversely affect neonatal outcomes or Apgar scores. The gas crosses the placenta but is rapidly eliminated by both mother and baby. However, nitrous oxide should be avoided during early pregnancy (first trimester) due to theoretical concerns about interference with DNA metabolism via B12 inactivation. Pregnant healthcare workers should also limit chronic occupational exposure.
The most common side effects include dizziness, light-headedness, euphoria, nausea, and vomiting. These effects are typically mild and resolve within minutes of stopping inhalation. Rare but clinically significant complications include diffusion hypoxia (transient oxygen desaturation when the gas is abruptly discontinued without oxygen supplementation) and vitamin B12 depletion with prolonged or repeated exposure, which can lead to megaloblastic anemia and neurological damage. These serious effects are preventable with appropriate clinical protocols.
Nitrous oxide is contraindicated in patients with pneumothorax, bowel obstruction, middle ear disease or recent middle ear surgery, maxillofacial injuries with air entrapment, decompression sickness, and severe vitamin B12 deficiency. It should not be used in patients with altered consciousness who cannot cooperate with self-administration. The fundamental reason for most contraindications is that nitrous oxide expands gas-filled spaces in the body – it is 34 times more soluble than nitrogen, so it diffuses into trapped gas pockets faster than nitrogen can leave, causing dangerous expansion.
Nitrous oxide has one of the fastest onset and offset profiles of any analgesic. Pain relief typically begins within 2–5 minutes of starting inhalation, with peak effect at approximately 3–5 minutes. After stopping, the gas is rapidly eliminated through the lungs, and effects wear off within 3–5 minutes. This rapid pharmacokinetic profile is due to the very low blood-gas partition coefficient of 0.47, meaning the gas equilibrates very quickly between the lungs and the blood. This makes nitrous oxide ideal for short procedures and situations requiring rapid recovery.
Yes, nitrous oxide is widely used and well-established for pediatric procedural sedation and analgesia. It is commonly used for emergency department procedures, dental treatments, wound care, fracture management, and minor surgery in children. The child must be old enough to understand and cooperate with the self-administration technique, typically from age 4–5 years. The self-administration requirement provides an inherent safety mechanism – if the child becomes excessively sedated, they release the mask and the effect rapidly wears off. Multiple guidelines, including those from the Royal College of Emergency Medicine and the American Academy of Pediatric Dentistry, endorse nitrous oxide for pediatric use.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Nitrous oxide listed as an essential anaesthetic agent.
- European Medicines Agency (EMA). European Pharmacopoeia monograph: Nitrous Oxide. Ph. Eur. 11th Edition. Quality standards for medicinal nitrous oxide.
- National Institute for Health and Care Excellence (NICE). Intrapartum care for healthy women and babies. NICE guideline CG190 (updated 2023). Section on nitrous oxide for labor analgesia.
- Becker DE, Rosenberg M. Nitrous oxide and the inhalation anaesthetics. Anesth Prog. 2008;55(4):124–131. doi:10.2344/0003-3006-55.4.124
- Tobias JD. Applications of nitrous oxide for procedural sedation in the pediatric population. Pediatr Emerg Care. 2013;29(2):245–265. doi:10.1097/PEC.0b013e318280d824
- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707–722. doi:10.1097/ALN.0b013e3181870a17
- Myles PS, Leslie K, Chan MT, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. Lancet. 2014;384(9952):1446–1454. doi:10.1016/S0140-6736(14)60893-X
- Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. Am J Obstet Gynecol. 2002;186(5 Suppl):S110–S126. doi:10.1067/mob.2002.121259
- European Society of Anaesthesiology and Intensive Care (ESAIC). Guidelines on procedural sedation and analgesia. Eur J Anaesthesiol. 2018;35(1):6–24.
- British National Formulary (BNF). Nitrous oxide. NICE Evidence Services. Accessed January 2026.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians and pharmacists with expertise in anaesthesiology, clinical pharmacology, and pain medicine.
Prepared by iMedic’s medical editorial team following the GRADE evidence framework. All clinical recommendations are based on systematic reviews, randomized controlled trials, and international guidelines (WHO, EMA, NICE, ESA).
Independently reviewed by the iMedic Medical Review Board, an independent panel of board-certified medical specialists who verify accuracy, completeness, and adherence to current evidence-based guidelines.
Last medical review:
Next scheduled review: